Fernando Centeno Malfaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fernando Centeno Malfaz has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
A.I. Beltrán Pérez
2 shared publicationsAlfonso Carmona Martínez
Instituto Hispalense de Pediatria, Edificio Expolocal, Sevilla, Spain
2 shared publicationsC González Armengod
2 shared publicationsC Navas Heredia
2 shared publicationsC. González Armengod
2 shared publicationsC. Navas Heredia
2 shared publications
Latest Publications
- Open Access
- 18 May 2026
- Published by Sociedad de Pediatría de Asturias, Cantabria y Castilla y León in Boletín de Pediatría
- Vol. 66 (275) , 1-6
Comunicación interauricular en edad pediátrica: características clínicas, manejo y resultados
Introduction and objectives: Atrial septal defects (ASDs) account for 6-10% of congenital heart defects. The most prevalent type, with the most variable clinical and therapeutic approach, is the ostium secundum(OS). The objective of this study is to describe the clinical and evolutionary characteristics, as well as the clinical and echocardiographic prognostic factors, of patients requiring closure of the defect. Materials and methods: Retrospective observational study of patients diagnosed with ASD. Variables studied: ASD type, size, age at diagnosis and at closure, and type of closure. Results: Predominance in males(55.4%), with OS being the most frequent(80.3%). 25% presented with heart failure during their follow-up, and 24.2% required nutritional support. At diagnosis, the mean age and size were 17.71 months and 6.5 mm. Spontaneous closure occurred in 15.2%, closure was achieved with a device in 24.2%, surgical closure was required in 30.3%. Ostium primum(OP) and sinus venosus(SV) ASDs required external closure. Age at closure was not a significant factor, but OS and SV were larger. OS ASDs were analyzed, revealing a 2.5-fold increased risk in males and a 7.33-fold increased risk of requiring closure in sizes >5 mm at diagnosis. No factors were found to indicate a preference for surgical or device-assisted closure. Conclusions: The most frequent ASD was type OS, with closure being more frequently in males and in those with a size greater than 5 mm at diagnosis, without finding prognostic factors for the type of closure. All OP and venous sinus ASDs required surgical closure.
- 18 May 2026
- Published by Sociedad de Pediatría de Asturias, Cantabria y Castilla y León in Boletín de Pediatría
- Vol. 66 (275) , 1-6
Open AccessComunicación interauricular en edad pediátrica: características clínicas, manejo y resultados
Introduction and objectives: Atrial septal defects (ASDs) account for 6-10% of congenital heart defects. The most prevalent type, with the most variable clinical and therapeutic approach, is the ostium secundum(OS). The objective of this study is to describe the clinical and evolutionary characteristics, as well as the clinical and echocardiographic prognostic factors, of patients requiring closure of the defect. Materials and methods: Retrospective observational study of patients diagnosed with ASD. Variables studied: ASD type, size, age at diagnosis and at closure, and type of closure. Results: Predominance in males(55.4%), with OS being the most frequent(80.3%). 25% presented with heart failure during their follow-up, and 24.2% required nutritional support. At diagnosis, the mean age and size were 17.71 months and 6.5 mm. Spontaneous closure occurred in 15.2%, closure was achieved with a device in 24.2%, surgical closure was required in 30.3%. Ostium primum(OP) and sinus venosus(SV) ASDs required external closure. Age at closure was not a significant factor, but OS and SV were larger. OS ASDs were analyzed, revealing a 2.5-fold increased risk in males and a 7.33-fold increased risk of requiring closure in sizes >5 mm at diagnosis. No factors were found to indicate a preference for surgical or device-assisted closure. Conclusions: The most frequent ASD was type OS, with closure being more frequently in males and in those with a size greater than 5 mm at diagnosis, without finding prognostic factors for the type of closure. All OP and venous sinus ASDs required surgical closure.
- Open Access
- 1 May 2022
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 15 (5) , e010075
Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy
Background: Maximal left ventricular wall thickness (MLVWT) is a risk factor for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM). In adults, the severity of left ventricular hypertrophy has a nonlinear relationship with SCD, but it is not known whether the same complex relationship is seen in childhood. The aim of this study was to describe the relationship between left ventricular hypertrophy and SCD risk in a large international pediatric HCM cohort. Methods: The study cohort comprised 1075 children (mean age, 10.2 years [±4.4]) diagnosed with HCM (1–16 years) from the International Paediatric Hypertrophic Cardiomyopathy Consortium. Anonymized, noninvasive clinical data were collected from baseline evaluation and follow-up, and 5-year estimated SCD risk was calculated (HCM Risk-Kids). Results: MLVWT Z score was Z scores were associated with heart failure symptoms, unexplained syncope, left ventricular outflow tract obstruction, left atrial dilatation, and nonsustained ventricular tachycardia. One hundred twenty-two patients (71.3%) with MLVWT Z score ≥20 had coexisting risk factors for SCD. Over a median follow-up of 4.9 years (interquartile range, 2.3–9.3), 115 (10.7%) had an SCD event. Freedom from SCD event at 5 years for those with MLVWT Z scores Z score, peaking at Z score +23. The presence of coexisting risk factors had a summative effect on risk. Conclusions: In children with HCM, an inverted U-shaped relationship exists between left ventricular hypertrophy and estimated SCD risk. The presence of additional risk factors has a summative effect on risk. While MLVWT is important for risk stratification, it should not be used either as a binary variable or in isolation to guide implantable cardioverter defibrillator implantation decisions in children with HCM.
- 1 May 2022
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 15 (5) , e010075
Open AccessRelationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy
Background: Maximal left ventricular wall thickness (MLVWT) is a risk factor for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM). In adults, the severity of left ventricular hypertrophy has a nonlinear relationship with SCD, but it is not known whether the same complex relationship is seen in childhood. The aim of this study was to describe the relationship between left ventricular hypertrophy and SCD risk in a large international pediatric HCM cohort. Methods: The study cohort comprised 1075 children (mean age, 10.2 years [±4.4]) diagnosed with HCM (1–16 years) from the International Paediatric Hypertrophic Cardiomyopathy Consortium. Anonymized, noninvasive clinical data were collected from baseline evaluation and follow-up, and 5-year estimated SCD risk was calculated (HCM Risk-Kids). Results: MLVWT Z score was Z scores were associated with heart failure symptoms, unexplained syncope, left ventricular outflow tract obstruction, left atrial dilatation, and nonsustained ventricular tachycardia. One hundred twenty-two patients (71.3%) with MLVWT Z score ≥20 had coexisting risk factors for SCD. Over a median follow-up of 4.9 years (interquartile range, 2.3–9.3), 115 (10.7%) had an SCD event. Freedom from SCD event at 5 years for those with MLVWT Z scores Z score, peaking at Z score +23. The presence of coexisting risk factors had a summative effect on risk. Conclusions: In children with HCM, an inverted U-shaped relationship exists between left ventricular hypertrophy and estimated SCD risk. The presence of additional risk factors has a summative effect on risk. While MLVWT is important for risk stratification, it should not be used either as a binary variable or in isolation to guide implantable cardioverter defibrillator implantation decisions in children with HCM.
- 1 July 2018
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 37 (7) , 704-714
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib and PHiD-CV When Coadministered With MenACWY-TT in Infants
Background: This study evaluated the immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus virus-Haemophilus influenzae type b vaccine (DTPa-HBV-IPV/Hib) and a 10-valent pneumococcal conjugate vaccine (PHiD-CV) coadministered with a quadrivalent meningococcal conjugate vaccine (MenACWY-TT) in infants/toddlers. Methods: In this open, controlled, phase III study (NCT01144663), 2095 healthy infants were randomized (1:1:1:1) into 4 groups to receive MenACWY-TT at 2, 3, 4 and 12 months of age or MenACWY-TT, MenC-CRM197, or MenC-TT at 2, 4 and 12 months of age. All participants received PHiD-CV and DTPa-HBV-IPV/Hib at 2, 3, 4 and 12 months of age. Immunogenicity of DTPa-HBV-IPV/Hib was evaluated in exclusive randomized subsets of 25% of participants from each group postprimary, prebooster and postbooster vaccination, whereas immunogenicity of PHiD-CV was evaluated at all time points. Reactogenicity was evaluated on the total vaccinated cohorts during 8 days after each vaccination. Results: For each DTPa-HBV-IPV/Hib antigen, ≥97.2%, ≥76.5% and ≥97.9% of participants had seropositive/seroprotective levels 1 month postprimary vaccination, before the booster dose and 1 month postbooster, respectively. For each vaccine pneumococcal serotype, ≥74.0% of infants had antibody concentrations ≥0.35 μg/mL at 1 month postprimary vaccination, and robust increases in antibody geometric mean concentrations were observed from prebooster to postbooster. Redness was the most frequent solicited local symptom at the DTPa-HBV-IPV/Hib and PHiD-CV injection sites, reported after up to 47.7% and 57.0% of doses postprimary and postbooster vaccination, respectively. Conclusions: Primary and booster vaccinations of infants/toddlers with DTPa-HBV-IPV/Hib and PHiD-CV coadministered with MenACWY-TT were immunogenic with clinically acceptable reactogenicity profiles. These results support the coadministration of MenACWY-TT with routine childhood vaccines.
- 1 July 2018
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 37 (7) , 704-714
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib and PHiD-CV When Coadministered With MenACWY-TT in Infants
Background: This study evaluated the immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus virus-Haemophilus influenzae type b vaccine (DTPa-HBV-IPV/Hib) and a 10-valent pneumococcal conjugate vaccine (PHiD-CV) coadministered with a quadrivalent meningococcal conjugate vaccine (MenACWY-TT) in infants/toddlers. Methods: In this open, controlled, phase III study (NCT01144663), 2095 healthy infants were randomized (1:1:1:1) into 4 groups to receive MenACWY-TT at 2, 3, 4 and 12 months of age or MenACWY-TT, MenC-CRM197, or MenC-TT at 2, 4 and 12 months of age. All participants received PHiD-CV and DTPa-HBV-IPV/Hib at 2, 3, 4 and 12 months of age. Immunogenicity of DTPa-HBV-IPV/Hib was evaluated in exclusive randomized subsets of 25% of participants from each group postprimary, prebooster and postbooster vaccination, whereas immunogenicity of PHiD-CV was evaluated at all time points. Reactogenicity was evaluated on the total vaccinated cohorts during 8 days after each vaccination. Results: For each DTPa-HBV-IPV/Hib antigen, ≥97.2%, ≥76.5% and ≥97.9% of participants had seropositive/seroprotective levels 1 month postprimary vaccination, before the booster dose and 1 month postbooster, respectively. For each vaccine pneumococcal serotype, ≥74.0% of infants had antibody concentrations ≥0.35 μg/mL at 1 month postprimary vaccination, and robust increases in antibody geometric mean concentrations were observed from prebooster to postbooster. Redness was the most frequent solicited local symptom at the DTPa-HBV-IPV/Hib and PHiD-CV injection sites, reported after up to 47.7% and 57.0% of doses postprimary and postbooster vaccination, respectively. Conclusions: Primary and booster vaccinations of infants/toddlers with DTPa-HBV-IPV/Hib and PHiD-CV coadministered with MenACWY-TT were immunogenic with clinically acceptable reactogenicity profiles. These results support the coadministration of MenACWY-TT with routine childhood vaccines.
- 1 April 2017
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 36 (4) , e98-e107
Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants
This was the first study evaluating the immunogenicity and safety of the quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) coadministered with routine childhood vaccines in young infants. In this open, randomized, controlled, phase III study (NCT01144663), 2095 infants (ages 6–12 weeks) were randomized (1:1:1:1) into 4 groups to receive MenACWY-TT at 2, 3, 4 and 12 months of age, or MenACWY-TT, MenC-cross-reactive material (CRM197) or MenC-TT at 2, 4 and 12 months of age. All participants received PHiD-CV and DTPa-HBV-IPV/Hib at 2, 3, 4 and 12 months of age. Immune responses were measured by serum bactericidal activity assays using rabbit (rSBA) and human (hSBA) complement. Solicited and unsolicited symptoms were recorded during 8 and 31 days post-vaccination, respectively, and serious adverse events throughout the study. Noninferiority of immune responses to MenC induced by 2 or 3 doses of MenACWY-TT versus 2 doses of MenC-TT or MenC-CRM197 was demonstrated. Predefined criteria for the immunogenicity of MenACWY-TT to MenA, MenW and MenY were met. One month after 2 or 3 primary MenACWY-TT doses, ≥93.1% and ≥88.5% of infants had rSBA and hSBA titers ≥1:8 for all serogroups. The robust increases in rSBA and hSBA titers observed for all vaccine serogroups postbooster vaccination suggested that MenACWY-TT induced immune memory. MenACWY-TT coadministered with childhood vaccines had a clinically acceptable safety profile. This study supports the coadministration of MenACWY-TT with routine childhood vaccines as 2 or 3 primary doses during infancy followed by a booster dose in the second year of life.
- 1 April 2017
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 36 (4) , e98-e107
Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants
This was the first study evaluating the immunogenicity and safety of the quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) coadministered with routine childhood vaccines in young infants. In this open, randomized, controlled, phase III study (NCT01144663), 2095 infants (ages 6–12 weeks) were randomized (1:1:1:1) into 4 groups to receive MenACWY-TT at 2, 3, 4 and 12 months of age, or MenACWY-TT, MenC-cross-reactive material (CRM197) or MenC-TT at 2, 4 and 12 months of age. All participants received PHiD-CV and DTPa-HBV-IPV/Hib at 2, 3, 4 and 12 months of age. Immune responses were measured by serum bactericidal activity assays using rabbit (rSBA) and human (hSBA) complement. Solicited and unsolicited symptoms were recorded during 8 and 31 days post-vaccination, respectively, and serious adverse events throughout the study. Noninferiority of immune responses to MenC induced by 2 or 3 doses of MenACWY-TT versus 2 doses of MenC-TT or MenC-CRM197 was demonstrated. Predefined criteria for the immunogenicity of MenACWY-TT to MenA, MenW and MenY were met. One month after 2 or 3 primary MenACWY-TT doses, ≥93.1% and ≥88.5% of infants had rSBA and hSBA titers ≥1:8 for all serogroups. The robust increases in rSBA and hSBA titers observed for all vaccine serogroups postbooster vaccination suggested that MenACWY-TT induced immune memory. MenACWY-TT coadministered with childhood vaccines had a clinically acceptable safety profile. This study supports the coadministration of MenACWY-TT with routine childhood vaccines as 2 or 3 primary doses during infancy followed by a booster dose in the second year of life.
- 1 November 2014
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 81 (5) , 275-282
Foetal bradycardia: A retrospective study in 9 Spanish centres
- 1 November 2014
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 81 (5) , 275-282
Foetal bradycardia: A retrospective study in 9 Spanish centres
- 1 March 2014
- Published by Elsevier in Anales de Pediatría
- Vol. 80 (3) , 187.e1-187.e5
Guía clínica para la prevención de la endocarditis infecciosa
- 1 March 2014
- Published by Elsevier in Anales de Pediatría
- Vol. 80 (3) , 187.e1-187.e5
Guía clínica para la prevención de la endocarditis infecciosa
- Open Access
- 28 February 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (S1) , P143
P88 ‐ Protocol implementation: effect on the assistance quality received by patients
- 28 February 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (S1) , P143
Open AccessP88 ‐ Protocol implementation: effect on the assistance quality received by patients
- Open Access
- 28 February 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (S1) , P125
P70 ‐ Testing adherence to asthma clinical guidelines in Spain
- 28 February 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (S1) , P125
Open AccessP70 ‐ Testing adherence to asthma clinical guidelines in Spain
- 1 October 2012
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 31 (10) , 1074-1077
Five-year Antibody Persistence and Safety Following a Booster Dose of Combined Haemophilus influenzae Type b–Neisseria meningitidis Serogroup C–Tetanus Toxoid Conjugate Vaccine
Booster vaccination with the combined Haemophilus influenza type b-Neisseria meningitides serogroup C-tetanus toxoid vaccine (Hib-MenC-TT) has been reported to induce different MenC antibody responses depending on the priming vaccines, with a possible impact on long-term protection. Here, the five-year persistence of immune responses induced by a booster dose of Hib-MenC-TT was evaluated in toddlers primed with either Hib-MenC-TT or MenC-TT. This is the follow-up of a phase III, open, randomized study, in which a Hib-MenC-TT booster dose was given at 13.14 months of age to toddlers primed with either 3 doses of Hib-MenC-TT or 2 doses of MenC-TT in infancy. Children in the control group had received 3 primary doses and a booster dose of MenC-CRM197. Functional antibodies against MenC were measured by a serum bactericidal assay with rabbit complement (rSBA-MenC) and antibodies against Hib polyribosylribitol phosphate by enzyme-linked immunosorbent assay. Serious adverse events considered by the investigator to be possibly related to vaccination were to be reported throughout the study. At 66 months postbooster, rSBA-MenC titers ≥8 were retained by 82.6% of children primed with Hib-MenC-TT, 94.1% of children primed with MenC-TT, and 60.9% of children in the control group. All children who received the Hib-MenC-TT booster dose retained anti- polyribosylribitol phosphate concentrations ≥0.15 μg/mL. No serious adverse events considered possibly related to vaccination were reported. There is evidence of good antibody persistence against MenC and Hib for more than five years postbooster vaccination with Hib-MenC TT in toddlers primed with Hib-MenC-TT or MenC-TT.
- 1 October 2012
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 31 (10) , 1074-1077
Five-year Antibody Persistence and Safety Following a Booster Dose of Combined Haemophilus influenzae Type b–Neisseria meningitidis Serogroup C–Tetanus Toxoid Conjugate Vaccine
Booster vaccination with the combined Haemophilus influenza type b-Neisseria meningitides serogroup C-tetanus toxoid vaccine (Hib-MenC-TT) has been reported to induce different MenC antibody responses depending on the priming vaccines, with a possible impact on long-term protection. Here, the five-year persistence of immune responses induced by a booster dose of Hib-MenC-TT was evaluated in toddlers primed with either Hib-MenC-TT or MenC-TT. This is the follow-up of a phase III, open, randomized study, in which a Hib-MenC-TT booster dose was given at 13.14 months of age to toddlers primed with either 3 doses of Hib-MenC-TT or 2 doses of MenC-TT in infancy. Children in the control group had received 3 primary doses and a booster dose of MenC-CRM197. Functional antibodies against MenC were measured by a serum bactericidal assay with rabbit complement (rSBA-MenC) and antibodies against Hib polyribosylribitol phosphate by enzyme-linked immunosorbent assay. Serious adverse events considered by the investigator to be possibly related to vaccination were to be reported throughout the study. At 66 months postbooster, rSBA-MenC titers ≥8 were retained by 82.6% of children primed with Hib-MenC-TT, 94.1% of children primed with MenC-TT, and 60.9% of children in the control group. All children who received the Hib-MenC-TT booster dose retained anti- polyribosylribitol phosphate concentrations ≥0.15 μg/mL. No serious adverse events considered possibly related to vaccination were reported. There is evidence of good antibody persistence against MenC and Hib for more than five years postbooster vaccination with Hib-MenC TT in toddlers primed with Hib-MenC-TT or MenC-TT.
- 3 May 2012
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 23 (5) , 441-447
Host and environmental factors influencing respiratory secretion of pro‐wheezing biomarkers in preterm children
To cite this article: Matías V, San Feliciano L, Fernández JE, Lapeña S, Garrido E, Ardura J, Soga MJ, Aragón MP, Remesal A, Benito F, Andrés J, Centeno F, Marugán V, Bachiller R, Bermejo‐Martin JF. Host and environmental factors influencing respiratory secretion of pro‐wheezing biomarkers in preterm children. Pediatric Allergy Immunology 2012: 23: 441–447. Cytokines are actively secreted by the respiratory mucosa of preterm children and participate in the pathogenesis of wheezing. This study aimed to identify the factors that could potentially influence respiratory secretion of cytokines in these children. A nasopharyngeal aspirate (NPA) was collected from 77 preterm children 1 yr after birth. NPAs from 14 healthy, 1‐yr‐old term children were collected in parallel. 27 cytokines were measured in the NPAs using a multiplex assay. Multivariate stepwise regression analysis with Bonferroni correction evidenced that the variable [daycare attendance] was associated with higher levels of [monocyte chemoattractant protein‐1 (MCP‐1), IL‐6, vascular endothelial growth factor (VEGF), IL‐1β, IL‐10, tumor necrosis factor (TNF)‐α]; [male sex] with higher levels of (MCP‐1, VEGF, and IL‐1β); [smokers at home] was associated with higher levels of MCP‐1 (p < 0.0013). In turn, [prophylaxis with palivizumab] was associated with lower levels of (IL‐6, IL‐7) (p < 0.0013). All these mediators participate in the pathogenesis of asthma and recurrent wheezing. Preterm children secreted higher levels of chemokines (interferon‐gamma inducible protein‐10, macrophage inflammatory protein‐1α, Eotaxin, MCP‐1), growth factors (platelet‐derived growth factor‐bb, VEGF, fibroblast growth factor‐basic, granulocyte macrophage colony‐stimulating factor), Th1 (IL12, interferon‐γ), Th2 (IL‐9, IL‐13), Th17 (IL‐6, IL‐17) cytokines, and immunomodulatory mediators (IL1RA and granulocyte colony‐stimulating factor) than term children. In conclusion, we have identified for the first time a group of individual and environmental factors influencing respiratory secretion of cytokines in preterm children at the long term after birth. To know these factors could help to prevent the instauration of conditions linked to the appearance of chronic respiratory diseases such as wheezing or asthma.
- 3 May 2012
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 23 (5) , 441-447
Host and environmental factors influencing respiratory secretion of pro‐wheezing biomarkers in preterm children
To cite this article: Matías V, San Feliciano L, Fernández JE, Lapeña S, Garrido E, Ardura J, Soga MJ, Aragón MP, Remesal A, Benito F, Andrés J, Centeno F, Marugán V, Bachiller R, Bermejo‐Martin JF. Host and environmental factors influencing respiratory secretion of pro‐wheezing biomarkers in preterm children. Pediatric Allergy Immunology 2012: 23: 441–447. Cytokines are actively secreted by the respiratory mucosa of preterm children and participate in the pathogenesis of wheezing. This study aimed to identify the factors that could potentially influence respiratory secretion of cytokines in these children. A nasopharyngeal aspirate (NPA) was collected from 77 preterm children 1 yr after birth. NPAs from 14 healthy, 1‐yr‐old term children were collected in parallel. 27 cytokines were measured in the NPAs using a multiplex assay. Multivariate stepwise regression analysis with Bonferroni correction evidenced that the variable [daycare attendance] was associated with higher levels of [monocyte chemoattractant protein‐1 (MCP‐1), IL‐6, vascular endothelial growth factor (VEGF), IL‐1β, IL‐10, tumor necrosis factor (TNF)‐α]; [male sex] with higher levels of (MCP‐1, VEGF, and IL‐1β); [smokers at home] was associated with higher levels of MCP‐1 (p < 0.0013). In turn, [prophylaxis with palivizumab] was associated with lower levels of (IL‐6, IL‐7) (p < 0.0013). All these mediators participate in the pathogenesis of asthma and recurrent wheezing. Preterm children secreted higher levels of chemokines (interferon‐gamma inducible protein‐10, macrophage inflammatory protein‐1α, Eotaxin, MCP‐1), growth factors (platelet‐derived growth factor‐bb, VEGF, fibroblast growth factor‐basic, granulocyte macrophage colony‐stimulating factor), Th1 (IL12, interferon‐γ), Th2 (IL‐9, IL‐13), Th17 (IL‐6, IL‐17) cytokines, and immunomodulatory mediators (IL1RA and granulocyte colony‐stimulating factor) than term children. In conclusion, we have identified for the first time a group of individual and environmental factors influencing respiratory secretion of cytokines in preterm children at the long term after birth. To know these factors could help to prevent the instauration of conditions linked to the appearance of chronic respiratory diseases such as wheezing or asthma.